Posted by rob on April 1, 2011 under Uncategorized | 
Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population, according to a new study. The article offers the first evidence that a disseminated cancer, not amenable to surgery, can be controlled to the point of giving patients a normal life expectancy. (Source: ScienceDaily Headlines)
MedWorm Message: Find out about the Doctors 2.0 and You conference in Paris, June 22-23rd. The call is now on for posters and the start-up contest.
More
Posted by rob on under Uncategorized |
Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online March 22 in the Journal of the National Cancer Institute. The article offers the first evidence that a disseminated cancer, not amenable to surgery, can be controlled to the point of giving patients a normal life expectancy… (Source: Health News from Medical News Today)
More
Posted by rob on under Uncategorized |
(Journal of the National Cancer Institute) Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online March 22 in the Journal of the National Cancer Institute. The article offers the first evidence that a disseminated cancer, not amenable to surgery, can be controlled to the point of giving patients a normal life expectancy. (Source: EurekAlert! – Cancer)
More
Posted by rob on under Uncategorized |
Conclusions Histopathologic analysis is not useful as a routine diagnostic tool in EM because no morphological changes are specific to EM. The capillary proliferation and vasculopathy are assumed to be a consequence of intermittent skin hypoxia (vascular hypothesis of pathogenesis). Whether the proliferation is a consequence of EM or a pathogenic factor in the development of the disease is uncertain. (Source: Archives of Dermatology)
More
Posted by rob on under Uncategorized |
Conclusion:
The present analysis documents the efficacy of RT. In addition, RT as a palliative treatment option for symptomatic SM should
not be forgotten.
Content Type Journal ArticlePages 1-4DOI 10.1007/s00066-011-2252-4Authors
Jan Kriz, Department of Radiation Oncology, University of Cologne, Cologne, GermanyOliver Micke, Department of Radiation Oncology, St. Franziskus Hospital, Bielefeld, GermanyFrank Bruns, Department of Radiation Oncology, Medical School Hannover, Hannover, GermanyUwe Haverkamp, Department of Radiology and Radiation Oncology, Clemens Hospital Münster, Münster, GermanyRalph Mücke, Department of Radiation Oncology, Hospital Lippe, Lippe, GermanyUlrich Schäfer, Department of Radiation Oncology, Hospital Lippe, Lippe, GermanyHeinrich Seegens…
More
Posted by rob on under Uncategorized |
The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib for chronic myelogenous leukemia in the accelerated phase (AP-CML) have not previously been evaluated. This cohort study was designed to compare the outcomes of imatinib (n = 87) versus allo-HSCT (n = 45) for AP-CML. A multivariate analysis of the total population revealed that a CML duration ≥ 12 months, hemoglobin < 100 g/L, and peripheral blood blasts ≥ 5% were independent adverse prognostic factors for both overall survival (OS) and progression-free survival (PFS). Both treatments resulted in similar survival in low-risk (no factor) patients, with 6-year event-free survival (EFS), OS, and PFS rates of more than 80.0%. Intermediate-risk (any factor) patients showed no difference i…
MedWorm Message: Find out about the Doctors 2.0 and You conference in Paris, June 22-23rd. The call is now on for posters and the start-up contest.
More
Posted by rob on under Uncategorized |
We describe a novel approach to targeting key proteins in CML cells with a ubiquitin-cycle inhibitor, WP1130. Bcr-Abl is rapidly modified with K63-linked ubiquitin polymers in WP1130-treated CML cells, resulting in its accumulation in aggresomes, where is it unable to conduct signal transduction. Induction of apoptosis because of aggresomal compartmentalization of Bcr-Abl was observed in both imatinib-sensitive and -resistant cells. WP1130, but not Bcr-Abl kinase inhibitors, directly inhibits Usp9x deubiquitinase activity, resulting in the down-regulation of the prosurvival protein Mcl-1 and facilitating apoptosis. These results demonstrate that ubiquitin-cycle inhibition represents a novel and effective approach to blocking Bcr-Abl kinase signaling and reducing Mcl-1 levels to engage CML …
More
Posted by rob on under Uncategorized |
Donor lymphocyte infusion (DLI), whereby donor mononuclear cells are infused into patients, is one of the few effective immunotherapeutic strategies that generate long-lasting tumor remissions. We previously demonstrated that chronic myelogenous leukemia (CML) patients treated with DLI develop high-titer plasma antibodies specific for CML-associated antigens, the majority of which have been reported to bind nucleic acids These observations led us to predict that circulating antibody-antigen complexes in DLI-responsive patients carry nucleic acids that can engage innate immune sensors. Consistent with this, we report here that post-DLI plasma from 5 CML patients that responded to DLI treatment induced massive upregulation of MIP-1α, IP-10, and IFN-α in normal blood mononucle…
More
Posted by rob on under Uncategorized |
Updated NCCN guidelines for chronic myelogenous leukemia (CML) name the second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib as front-treatment for CML. Medscape Medical News (Source: Medscape Today Headlines)
More
Posted by rob on under Uncategorized |
Second generation tyrosine kinase inhibitor (TKI) therapies approved for first-line therapy of chronic myelogenous leukemia (CML) offer newly diagnosed patients an expanded range of treatment options, according to Susan O’Brien, MD, of The University of Texas MD Anderson Cancer Center and chair of the NCCN Guidelines™ for CML. Dr. O’Brien emphasized the considerable advances made in the treatment of CML during her presentation of the updated NCCN Guidelines for CML at the NCCN 16th Annual Conference on March 11, 2011… (Source: Health News from Medical News Today)
More
Posted by rob on under Uncategorized |
New first-line therapies for patients with CML highlight notable updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for CML at the National Comprehensive Cancer Network® (NCCN®) 16th Annual Conference.
HOLLYWOOD, FL – Second generation tyrosine kinase inhibitor (TKI) therapies approved for first-line therapy of chronic myelogenous leukemia (CML) offer newly diagnosed patients an expanded range of treatment options, according to Susan O’Brien, MD, of The Universi… (Source: National Comprehensive Cancer Network)
MedWorm Message: Find out about the Doctors 2.0 and You conference in Paris, June 22-23rd. The call is now on for posters and the start-up contest.
More
Posted by rob on under Uncategorized |
AbstractBcr?Abl activates various signaling pathways in chronic myelogenous leukemia (CML) cells. The proliferation of Bcr?Abl transformed cells is promoted by c?Myc through the activation of Akt, JAK2 and NF??B. However, the mechanism by which c?Myc regulates CML cell proliferation is unclear. In the present study, we investigated the role of thanatos?associated protein 11 (THAP11), which inhibits c?Myc transcription, in CML cell lines and in hematopoietic progenitor cells derived from CML patients. The induction of THAP11 expression by Abl kinase inhibitors in CML cell lines and in CML?derived hematopoietic progenitor cells resulted in the suppression of c?Myc. In addition, over?expression of THAP11 inhibited CML cell proliferation. In colony forming cells derived fr…
More
Posted by rob on under Uncategorized |
The high school junior’s life was turned upside down. But she was determined to not fall into depression.My life drastically changed two weeks into my junior year of high school, when I was diagnosed with chronic myelogenous leukemia, a rare blood cancer. (Source: L.A. Times – Health)
More
Posted by rob on under Uncategorized |
LITTLE ROCK, Ark. – In an opinion entered Feb. 17, the Arkansas Supreme Court affirmed a verdict against the parents of a child diagnosed with chronic myelogenous leukemia who allege that exposure to organic arsenic from chicken litter spread on farm fields caused the cancer (Mary E. Green, et al. v. George’s Farm Inc, et al., No. 10-26; Ark. Sup.; 2011 Ark. LEXIS 65; See 5/20/08, Page 4).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Emerging Toxic Torts Legal News)
More
Posted by rob on under Uncategorized |
We describe 10 patients with CML in hematologic and cytogenetic remission with del(20q) detected by conventional cytogenetics. There were 6 men and 4 women with a median age of 56 years. All patients initially had BCR-ABL1 and t(9;22) (q34;q11.2) and achieved morphologic and cytogenetic remission after therapy. del(20q) was identified before (2/10 [20%]), at the time of (3/10 [30%]), or after (5/10 [50%]) cytogenetic remission and was not associated with morphologic evidence of dysplasia. At last follow-up, no patients had a myelodysplastic syndrome (MDS). Leukocyte and platelet counts were normal; 4 of 10 patients had mild anemia. Nine patients have remained in morphologic and cytogenetic remission with stable del(20q). BCR-ABL1 fusion transcript levels were absent or low (median, 0.01%)….
More
Posted by rob on under Uncategorized |
(Source: CA: A Cancer Journal for Clinicians)
MedWorm Message: Find out about the Doctors 2.0 and You conference in Paris, June 22-23rd. The call is now on for posters and the start-up contest.
More
Posted by rob on under Uncategorized |
Abstract Molecular monitoring is a key component of the management of patients with chronic myeloid leukemia. The current recommendation
is that molecular monitoring be performed in place of cytogenetic assessment when a major molecular response (MMR) is achieved.
With the more potent kinase inhibitors nilotinib and dasatinib now approved as front-line therapy, more patients will achieve
an MMR and will benefit from molecular monitoring. There is a strong correlation between certain BCR-ABL1 levels and the cytogenetic response, which means that molecular monitoring may act as a surrogate for cytogenetic response,
but only if the BCR-ABL1 values are converted to the international reporting scale. Furthermore, improvements in the limit of BCR-ABL1 detection and reduction of in…
More
Posted by rob on under Uncategorized |
In conclusion, PTEN could modulate
the function of VEGF/VEGFR signaling pathway down-regulation of Akt phosphorylation and that PTEN would be a candidate target
to be addressed for inhibiting angiogenesis along with the treatment of myeloid leukemia.
Content Type Journal ArticlePages 1-9DOI 10.1007/s12032-011-9867-2Authors
Cheng Zhiyong, Department of Hematology, The First Hospital of Baoding, 966 Baihua Road, 050000 Baoding, ChinaLiang Wentong, Department of Hematology, The First Hospital of Baoding, 966 Baihua Road, 050000 Baoding, ChinaYang Xiaoyang, Department of Hematology, Affiliated Haikou Hospital, Central South University, Haikou Municipal Hospital, 43# People’s Road Haidian Island, 5702083 Haikou, ChinaPan Ling, Department of Hematology, West China Hospital, Sichuan Un…
More
Posted by rob on under Uncategorized |
AbstractDisease overview:Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms primarily characterized by erythrocytosis and thrombocytosis, respectively. Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, pruritus, and a small risk of disease progression into acute leukemia or myelofibrosis.Diagnosis:Diagnosis is based on JAK2 mutation status (PV and ET), serum erythropoietin (Epo) level (PV), and bone marrow histopathology (ET). The presence of a JAK2 mutation and subnormal serum Epo level confirm a diagnosis of PV. Differential diagnosis in ET should include chronic myelogenous leukemia and prefibrotic myelofibrosis.Risk stratification:Current risk stratification in PV and ET is design…
More
Posted by rob on under Uncategorized |
Abstract Cancer chemotherapy was introduced at the same time as antibacterial chemotherapy but has not been nearly such a success.
However, there is a growing optimism in oncology today due to the introduction of several more or less target-specific drugs
as complements to the conventional cytotoxic drugs introduced half a century ago. The success in the treatment of chronic
myelogenous leukemia by imatinib, inhibiting the bcr-abl-activated tyrosine kinase and thereby interrupting the signal transduction
pathways that lead to leukemic transformation with impressive survival benefit, has paved the way for this new optimism. Another
success story is the introduction of trastuzumab in breast cancers overexpressing the HER-2 receptor. In contrast, there has
been little progres…
More
